We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Malaria Test Assessed in Nonendemic Setting

By LabMedica International staff writers
Posted on 23 May 2011
A rapid diagnostic test (RDT) for malaria has been evaluated in a standard reference laboratory using stored and fresh blood samples. More...


In nonendemic settings, where microscopic expertise is lacking due to low incidence, malaria RDTs are of value for the diagnosis of malaria and they provide information about the possibly fatal Plasmodium falciparum infections.

Scientists at Maastricht University, (Maastricht, The Netherlands), performed both a retrospective study on 341 stored blood samples and prospective study. In the prospective study, the SD Bioline Malaria Ag 05FK40, (SDFK40), RDT was used on 181 fresh samples and run side by side with two other RDTs, OptiMAL and SDFK60. The SDFK40 is a lateral flow antigen-detection test in a cassette format, targeting P. falciparum-specific parasite lactate dehydrogenase (Pf-pLDH) and pan-Plasmodium LDH, (pan-pLDH). The prospective part was performed between March 2009 and October 2010, and included first samples of each patient for which microscopy or one of the both routinely used RDTs (OptiMAL and SDFK60) were positive for malaria.

Overall sensitivities for P. falciparum tested retrospectively and prospectively were 67.9% and 78.8%, reaching 100% and 94.6% at parasite densities greater than 1,000/μL. Sensitivity at parasite densities less than 100/μL was 9.1%. Overall sensitivities for P. vivax and P. ovale were 86.7% and 80.0% (retrospectively) and 92.9% and 76.9% (prospectively), reaching 94.7% for both species (retrospective panel) at parasite densities greater than 500/μL. Sensitivity for P. malariae was 21.4%. None of the Plasmodium negative samples in the retrospective panel reacted positive.

The authors concluded that SDFK40 RDT (Standard Diagnostics Inc.; Suwon, Korea), performed exceptionally for P. falciparum samples at high parasite densities as well as for detection of P. vivax and P. ovale at parasite densities greater than 500/μL. The SDFK40 was evaluated as easy to use, with an excellent clearance of the background and clearly visible test lines. Compared to OptiMAL Rapid Malaria test, (Diamed AG; Cressier, Switzerland), and Standard Diagnostics other RDT, called SD Bioline Ag Pf/Pan 05FK60 (SDFK60), SDFK40 showed lower sensitivities for P. falciparum, but better detection of P. ovale. The study was published online on January 12, 2011, in the Malaria Journal.

Related Links:
Maastricht University
Standard Diagnostics Inc.
Diamed AG



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.